PALB2 p.Val627=
c.1881G>T · rs139362268 · VCV126626
Computational evidence
| Protein change | ||
| Missense predictors do not apply to this variant type; conservation carries the signal. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
|---|---|---|
| Constraint at this position | ||
| Conservation | phyloP 0.12 | GERP 0.9, phastCons 0.94 |
| Overall | ||
| CADD | 5.516 | PHRED · no single calibrated threshold — expert panels disagree |
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Ashkenazi Jewishnot grpmax-eligible | 0.382% | 262 |
| Remaining individualsnot grpmax-eligible | 0.0288% | 3,472 |
| European (non-Finnish)grpmax | 0.00144% | 69,413 |
Ashkenazi Jewish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- PALB2
- Protein
- p.Val627=
- Coding
- c.1881G>T
- MANE Select
- NM_024675
- dbSNP
- rs139362268
- Type
- single nucleotide variant
- Location
- chr16:23630273 (GRCh38)
- Gene constraint
- LOEUF 0.9 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
- Structure
- AlphaFold pLDDT 54.07 · 4 PDB
- Residue 627
- a UniProt-annotated variant site (risk factor for brovca5); a UniProt-annotated variant site (in fancn; risk factor for brovca5); an α-helix
Disease context
Breast and/or ovarian cancer — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: colon carcinomaendometrial carcinomaFanconi anemia complementation group Npancreatic cancer, susceptibility to, 3hereditary neoplastic syndromehereditary breast carcinoma
Similar variants
- PALB2 p.Val627Ala Uncertain significance ★★ ⚠ same residue
- PALB2 p.Val627Gly Uncertain significance ★★ ⚠ same residue
- PALB2 p.Val627Met Uncertain significance ★★ ⚠ same residue
- PALB2 p.Val627Leu Conflicting classifications of pathogenicity ★ ⚠ same residue
- PALB2 p.Val627fs Pathogenic/Likely pathogenic ★★ same residue
- PALB2 c.3350+4A>G Likely pathogenic ★★★ same condition
- PALB2 p.Arg1117Lys Pathogenic ★★★ ⚠ same condition
- PALB2 p.Gln228Ter Pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/palb2-p-val627 (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown